Paving the Way Toward Meaningful Trials in Ataxias: An Ataxia Global Initiative Perspective

• Dr. Thomas Klockgether, with Dr. Bernard Brais (NMD4C) as a co-author.

2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders

• Dr. William Groh, with Dr. Hugh McMillan (NMD4C) as a co-author.

Genetic testing for amyotrophic lateral sclerosis in Canada - an assessment of current practices

• Dr. Kristiana Salmon, with Dr. Aaron Izenberg (NMD4C) as a co-author.

MicroRNAs in oligodendrocyte development and remyelination

• Dr. Clarissa Ngo, with Dr. Rashmi Kothary (NMD4C) as a co-author.

Genitourinary and lower gastrointestinal conditions in patients with myotonic dystrophy type 1: A systematic review of evidence and implications for clinical practice

• Isabelle Fisette-Paulhus, with Dr. Cynthia Gagnon (NMD4C) as a co-author.

Curing SMA: Are we there yet?

• Aoife Reilly, with Dr. Rashmi Kothary (NMD4C) as a co-author.

Gold Coast Criteria Expand Clinical Trial Eligibility in Amyotrophic Lateral Sclerosis

• Dr. Gordon Jewett, with Drs. Victoria Hodgkinson & Lawrence Korngut (#NMD4C) as co-authors.

Natural history of a mouse model of X-linked myotubular myopathy

• Dr. Ege Sarikaya, with Drs Hernan Gonorazky & James Dowling (NMD4C) as co-authors.

INCEPTUS Natural History, Run-in Study for Gene Replacement Clinical Trial in X-Linked Myotubular Myopathy

• Dr. James Dowling (NMD4C)

Variants in ASPH cause exertional heat illness and are associated with malignant hyperthermia susceptibility

• Dr. Yukari Endo, with Dr. James Dowling (NMD4C) as a co-author.

Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patients

• Dr. Aymeric Ravel-Chapuis, with Dr. Elise Duchesne (NMD4C) as a co-author.

Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States

• Dr. Komal Bharti, with Dr. Lawrence Korngut (NMD4C) as a co-author.

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

• Dr. Kevin Strauss, with Dr. Hugh McMillan (NMD4C) as a co-author.

Case Report: Severe Peripartum Cardiac Disease in Myotonic Dystrophy Type 1

• Dr. Georgia Besant, with Dr. Jodi Warman Chardon & Dr. Hanns Lochmüller (NMD4C) as co-authors.